Targeted News Service

Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA(r) (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer
July 03, 2025

NEW BRUNSWICK, New Jersey, July 3 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA(r) (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations

*

BEERSE, BELGIUM (3 July 2025) . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form